Nicotine metabolism-informed care for smoking cessation: A pilot precision RCT

Nicotine and Tobacco Research

Volumn 20, Issue 12, 2018, Pages 1489-1496

  Wells, Quinn S ^a   Freiberg, Matthew S ^a   Greevy, Robert A ^a   Tyndale, Rachel F ^b   Kundu, Suman ^a   Duncan, Meredith S ^a   King, Stephen ^a   Abney, Lesa ^a   Scoville, Elizabeth ^a   Beaulieu, Dawn B ^a   Gatskie, Vanessa ^a   Tindle, Hilary A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE; NICOTINE; NICOTINIC AGENT;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL OUTCOME; COMORBIDITY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; METABOLISM INFORMED CARE; METABOLITE; OUTPATIENT CARE; PATIENT CARE; PATIENT COUNSELING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; DRUG THERAPY; FOLLOW UP; METABOLISM; MIDDLE AGED; PERSONALIZED MEDICINE; PILOT STUDY; PROCEDURES; SMOKING;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PILOT PROJECTS; PRECISION MEDICINE; SMOKING CESSATION; SMOKING CESSATION AGENTS; TOBACCO SMOKING; TOBACCO USE CESSATION DEVICES; VARENICLINE;

EID: 85044781686     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntx235     Document Type: Article

References (25)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238–1245.
2. Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current cigarette smoking among adults - United States, 2005-2015. MMWR Morb Mortal Wkly Rep. 2016;65(44):1205–1211.
3. Steinberg MB, Akincigil A, Delnevo CD, Crystal S, Carson JL. Gender and age disparities for smoking-cessation treatment. Am J Prev Med. 2006;30(5):405–412.
4. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34(2):102–111.
5. Bauld L, Bell K, McCullough L, Richardson L, Greaves L. The effectiveness of NHS smoking cessation services: a systematic review. J Public Health (Oxf). 2010;32(1):71–82.
6. rd, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1):64–72.
7. Gambier N, Batt AM, Marie B, Pfister M, Siest G, Visvikis-Siest S. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics J. 2005;5(4):271–275.
8. West O, Hajek P, McRobbie H. Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. Psychopharmacology (Berl). 2011;218(2):313–322.
9. Strasser AA, Benowitz NL, Pinto AG, et al. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev. 2011;20(2):234–238.
10. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92(1):6–11.
11. Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009;85(6):635–643.
12. Patterson F, Schnoll RA, Wileyto EP, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther. 2008;84(3):320–325.
13. Lerman C, Schnoll RA, Hawk LW Jr, et al.; PGRN-PNAT Research Group. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3(2):131–138.
14. rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79–115.
15. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57–71.
16. Perkins KA, Karelitz JL, Jao NC. Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence. Nicotine Tob Res. 2013;15(5): 978–982.
17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
18. Gwaltney CJ, Metrik J, Kahler CW, Shiffman S. Self-efficacy and smoking cessation: a meta-analysis. Psychol Addict Behav. 2009;23(1):56–66.
19. Borland R, Yong HH, O’Connor RJ, Hyland A, Thompson ME. The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study. Nicotine Tob Res. 2010;12 (Suppl):S45–S50.
20. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–1292.
21. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56(4):423–432.
22. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–2520.
23. Hughes JR. An updated algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat. 2013;45(2):215–221.
24. Huang Y, Lewis S, Britton J. Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis. BMC Public Health. 2014;14:1024.
25. Kuehn BM. Pilot Programs Seek to Integrate Genomic Data Into Practice. JAMA. 2017;318(5):410–412.